Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Expanding roles for CD4 T cells and their subpopulations in tumor immunity and therapy.

Dobrzanski MJ.

Front Oncol. 2013 Mar 26;3:63. doi: 10.3389/fonc.2013.00063. eCollection 2013.

2.

Cytotoxic T-lymphocyte immunotherapy for ovarian cancer: a pilot study.

Wright SE, Rewers-Felkins KA, Quinlin IS, Phillips CA, Townsend M, Philip R, Dobrzanski MJ, Lockwood-Cooke PR, Robinson W.

J Immunother. 2012 Feb-Mar;35(2):196-204. doi: 10.1097/CJI.0b013e318243f213.

3.

Immunotherapy with IL-10- and IFN-γ-producing CD4 effector cells modulate "Natural" and "Inducible" CD4 TReg cell subpopulation levels: observations in four cases of patients with ovarian cancer.

Dobrzanski MJ, Rewers-Felkins KA, Samad KA, Quinlin IS, Phillips CA, Robinson W, Dobrzanski DJ, Wright SE.

Cancer Immunol Immunother. 2012 Jun;61(6):839-54. doi: 10.1007/s00262-011-1128-x. Epub 2011 Nov 15.

4.

Autologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survival.

Dobrzanski MJ, Rewers-Felkins KA, Quinlin IS, Samad KA, Phillips CA, Robinson W, Dobrzanski DJ, Wright SE.

Clin Immunol. 2009 Dec;133(3):333-52. doi: 10.1016/j.clim.2009.08.007. Epub 2009 Sep 16.

5.

Ag-specific type 1 CD8 effector cells enhance methotrexate-mediated antitumor responses by modulating endogenous CD49b-expressing CD4 and CD8 T effector cell subpopulations producing IL-10.

Dobrzanski MJ, Reome JB, Hylind JC, Rewers-Felkins KA, Abdulsamad K, Adams SL.

Immunol Invest. 2008;37(4):315-38. doi: 10.1080/08820130802083762.

PMID:
18569073
6.

Ag-specific type 1 CD8 effector cells enhance methotrexate-mediated antitumor responses by modulating differentiated T cell localization, activation and chemokine production in established breast cancer.

Dobrzanski MJ, Reome JB, Hylind JC, Rewers-Felkins KA, Abulsamad K, Adams SL.

Clin Immunol. 2008 Aug;128(2):205-18. doi: 10.1016/j.clim.2008.03.518. Epub 2008 Jun 3.

PMID:
18511346
8.

Type 1 and type 2 tumor infiltrating effector cell subpopulations in progressive breast cancer.

Reome JB, Hylind JC, Dutton RW, Dobrzanski MJ.

Clin Immunol. 2004 Apr;111(1):69-81.

PMID:
15093554
9.
10.
11.
12.
13.
14.
15.
16.

Peptide-specific activation of cytolytic CD4+ T lymphocytes against tumor cells bearing mutated epitopes of K-ras p21.

Abrams SI, Dobrzanski MJ, Wells DT, Stanziale SF, Zaremba S, Masuelli L, Kantor JA, Schlom J, Masuelle L [corrected to Masuelli L].

Eur J Immunol. 1995 Sep;25(9):2588-97. Erratum in: Eur J Immunol 1995 Dec;25(12):3525.

PMID:
7589131
19.
20.
21.

Supplemental Content

Loading ...
Support Center